However, response to treatment as assessed by the percentage reduction in PSA did prove significantly lower at a higher age and unrelated to the number of treatment cycles administered in favor of a more aggressive character of the underlying prostate carcinoma in these patients. This evidence concerns the gene KLK3 and prostate carcinoma.